Safety and efficacy of semaglutide once weekly vs sitagliptin once daily, both as monotherapy in Japanese people with type 2 diabetes

Diabetes, Obesity and Metabolism

Volumn 20, Issue 2, 2018, Pages 378-388

  Seino, Yutaka ^a,b   Terauchi, Yasuo ^c   Osonoi, Takeshi ^d   Yabe, Daisuke ^a,b,e   Abe, Nobuyuki ^f   Nishida, Tomoyuki ^g   Zacho, Jeppe ^g   Kaneko, Shizuka ^h  

^a Kobe Biotechnology Research and Human Resource Development Center   (Japan)

^b KANSAI ELECTRIC POWER CO   (Japan)

^c YOKOHAMA CITY UNIVERSITY   (Japan)

^d Naka Kinen Clinic   (Japan)

^e KYOTO UNIVERSITY   (Japan)

^f Abe Clinic   (Japan)

^g Novo Nordisk Pharma Ltd   (Japan)

^h TAKATSUKI RED CROSS HOSPITAL   (Japan)

Author keywords

GLP 1; sitagliptin; type 2 diabetes

Indexed keywords

CALCITONIN; GLUCOSE; HEMOGLOBIN A1C; SEMAGLUTIDE; SITAGLIPTIN; DIPEPTIDYL PEPTIDASE IV INHIBITOR; GLP1R PROTEIN, HUMAN; GLUCAGON LIKE PEPTIDE; GLUCAGON LIKE PEPTIDE 1 RECEPTOR; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C PROTEIN, HUMAN; INCRETIN;

ABSENCE OF SIDE EFFECTS; ADULT; ARTICLE; BLADDER CANCER; BODY MASS; BODY WEIGHT; CHOLELITHIASIS; CONSTIPATION; CONTROLLED STUDY; DIABETIC RETINOPATHY; DIARRHEA; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG SAFETY; FEMALE; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HEART INFARCTION; HUMAN; HYPOGLYCEMIA; INFORMED CONSENT; JAPANESE (PEOPLE); MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; NEUROLOGIC DISEASE; NON INSULIN DEPENDENT DIABETES MELLITUS; OPEN STUDY; PANCREAS CARCINOMA; PHASE 3 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; REVASCULARIZATION; SIDE EFFECT; SYSTOLIC BLOOD PRESSURE; AGONISTS; BLOOD; BODY WEIGHT LOSS; CHEMICALLY INDUCED; CLINICAL TRIAL; COMPARATIVE STUDY; DOSE RESPONSE; DRUG ADMINISTRATION; DRUG EFFECT; ETHNOLOGY; FOLLOW UP; HYPERGLYCEMIA; JAPAN; METABOLISM; ORAL DRUG ADMINISTRATION; PATHOPHYSIOLOGY; PATIENT DROPOUT; SEVERITY OF ILLNESS INDEX; SUBCUTANEOUS DRUG ADMINISTRATION;

ADMINISTRATION, ORAL; CONSTIPATION; DIABETES MELLITUS, TYPE 2; DIARRHEA; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FOLLOW-UP STUDIES; GLUCAGON-LIKE PEPTIDE-1 RECEPTOR; GLUCAGON-LIKE PEPTIDES; GLYCATED HEMOGLOBIN A; HUMANS; HYPERGLYCEMIA; HYPOGLYCEMIA; INCRETINS; INJECTIONS, SUBCUTANEOUS; JAPAN; NAUSEA; PATIENT DROPOUTS; SEVERITY OF ILLNESS INDEX; SITAGLIPTIN PHOSPHATE; WEIGHT LOSS;

EID: 85040743855     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/dom.13082     Document Type: Article

References (45)

1. Mukai N, Doi Y, Ninomiya T, et al. Trends in the prevalence of type 2 diabetes and prediabetes in community-dwelling Japanese subjects: the Hisayama Study. J Diabetes Invest. 2014;5(2):162–169.
2. Stark Casagrande S, Fradkin JE, Saydah SH, Rust KF, Cowie CC. The prevalence of meeting A1c, blood pressure, and LDL goals among people with diabetes, 1988–2010. Diabetes Care. 2013;36(8):2271–2279.
3. Handelsman Y, Bloomgarden ZT, Grunberger G, et al. American Association of Clinical Endocrinologists and American College of Endocrinology – clinical practice guidelines for developing a diabetes mellitus comprehensive care plan – 2015. Endocr Pract. 2015;21(suppl 1):1–87.
4. Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2015;38(1):140–149.
5. Prasad-Reddy L, Isaacs D. A clinical review of GLP-1 receptor agonists: efficacy and safety in diabetes and beyond. Drugs Context. 2015;4:212283. https://doi.org/10.7573/dic.212283.
6. Kapitza C, Nosek L, Jensen L, et al. Semaglutide, a once-weekly human GLP-1 analog, does not reduce the bioavailability of the combined oral contraceptive, ethinylestradiol/levonorgestrel. J Clin Pharmacol. 2015;55(5):497–504.
7. Marbury TC, Flint A, Segel S, Lindegaard M, Lasseter KC. Abstracts of the 50th EASD Annual Meeting, September 15–19, 2014, Vienna, Austria. Diabetologia. 2014;57(suppl 1):S358.
8. Inukai K, Hirata T, Sumita T, et al. Clinical characteristics of Japanese type 2 diabetic patients responsive to sitagliptin. J Diabetes Mellitus. 2014;4:172–178.
9. Seino Y, Yabe D. Glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1: incretin actions beyond the pancreas. J Diabetes Investig. 2013;4(2):108–130.
10. Sorli C, Harashima SI, Tsoukas GM, et al. Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1): a double-blind, randomised, placebo-controlled, parallel-group, multinational, multicentre phase 3a trial. Lancet Diabetes Endocrinol. 2017;5(4):251–260.
11. Ahrén B, Masmiquel L, Kumar H, et al. Efficacy and safety of once-weekly, subcutaneous semaglutide versus oral sitagliptin as add-on to metformin and/or thiazolidinediones in subjects with type 2 diabetes (SUSTAIN 2): a 56-week randomised, controlled clinical trial. Lancet Diabetes Endocrinol. 2017;5(5):341–354.
12. Ahmann AJ, Capehorn M, Charpentier G, et al. Efficacy and safety of once-weekly semaglutide vs exenatide ER after 56 weeks in subjects with type 2 diabetes (SUSTAIN 3). American Diabetes Association – 76th Annual Scientific Sessions; New Orleans, LA, USA, 2016;65(suppl 1):A49.
13. Aroda VR, Bain SC, Cariou B, et al. Efficacy and safety of once-weekly semaglutide versus once-daily insulin glargine as add-on to metformin (with or without sulphonylureas) in insulin-naive patients with type 2 diabetes (SUSTAIN 4): a randomised, open-label, parallel-group, multicentre, multinational, phase 3a trial. Lancet Diabetes Endocrinol. 2017;5(5):355–366.
14. Rodbard H, Lingvay I, Reed J, et al. Efficacy and safety of semaglutide once-weekly vs placebo as add-on to basal insulin alone or in combination with metformin in subjects with type 2 diabetes (SUSTAIN 5). Diabetologia. 2016;59(suppl 1):S364–S365.
15. Marso SP, Bain SC, Consoli A, et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2016;10(375):1834–1844.
16. ClinicialTrials.gov. A trial comparing the safety and efficacy of semaglutide once weekly in monotherapy or in combination with one OAD in Japanese subjects with type 2 diabetes (SUSTAIN™). 2014. https://clinicaltrials.gov/ct2/show/NCT02207374. Accessed September 20, 2017.
17. ClinicialTrials.gov. A trial comparing the safety and efficacy of semaglutide once weekly versus sitagliptin once daily in Japanese subjects with type 2 diabetes (SUSTAIN™). 2014. https://clinicaltrials.gov/ct2/show/NCT02254291. Accessed September 20, 2017.
18. Ministry of Health, Labour and Welfare. Guideline for Clinical Evaluation of Oral Hypoglycaemic Agents. 2010. Pharmaceuticals and Medical Devices Agency, Tokyo, Japan. https://www.pmda.go.jp/files/000208194.pdf. Accessed September 20, 2017.
19. European Agency for the Evaluation of Medicinal Products. International Conference on Harmonisation-World Health Organization guideline for good clinical practice [EMEA Web site] ICH harmonised tripartite guideline good clinical practice. 2016. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500002874.pdf. Accessed September 20, 2017.
20. World Medical Association. Declaration of Helsinki ethical principles for medical research involving human subjects. Last amended by the 59th WMA General Assembly, Seoul, Republic of Korea. 2008. https://www.wma.net/policies-post/wma-declaration-of-helsinki-ethical-principles-for-medical-research-involving-human-subjects/. Accessed September 20, 2017.
21. Garber AJ, Abrahamson MJ, Barzilay JI, et al. Consensus statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the comprehensive type 2 diabetes management algorithm – 2017 executive summary. Endocr Pract. 2017;23:207–238.
22. American Diabetes Association. Standards of medical care in diabetes – 2016. Diabetes Care. 2016;39(suppl 1):S1–S112.
23. The Japan Diabetes Society. Evidence-based practice guideline for the treatment for diabetes in Japan 2013. http://www.jds.or.jp/modules/en/index.php?content_id=44. Accessed September 20, 2017.
24. Marre M, Shaw J, Brändle M, et al. Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU). Diabet Med. 2009;26(3):268–278.
25. Nauck M, Frid A, Hermansen K, et al. Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study. Diabetes Care. 2009;32(1):84–90.
26. Nauck MA, Petrie JR, Sesti G, et al. A phase 2, randomized, dose-finding study of the novel once-weekly human GLP-1 analog, semaglutide, compared with placebo and open-label liraglutide in patients with type 2 diabetes. Diabetes Care. 2016;39(2):231–241.
27. Ahmad SR, Swann J. Exenatide and rare adverse events. N Engl J Med. 2008;358(18):1970–1971.
28. Cefalu WT, Buse JB, Del Prato S, et al. Beyond metformin: safety consideration in the decision making process for selecting a second medication for type 2 diabetes management. Reflections from a diabetes care editors' expert forum. Diabetes Care. 2014;37(9):2647–2659.
29. Garg R, Chen W, Pendergrass M. Acute pancreatitis in type 2 diabetes treated with exenatide or sitagliptin: a retrospective observational pharmacy claims analysis. Diabetes Care. 2010;33(11):2349–2354.
30. Dore DD, Seeger JD, Arnold CK. Use of a claims-based active drug safety surveillance system to assess the risk of acute pancreatitis with exenatide or sitagliptin compared to metformin or glyburide. Curr Med Res Opin. 2009;25(4):1019–1027.
31. Dore DD, Bloomgren GL, Wenten M, et al. A cohort study of acute pancreatitis in relation to exenatide use. Diabetes Obes Metab. 2011;13(6):559–566.
32. Wenten M, Gaebler JA, Hussein M, et al. Relative risk of acute pancreatitis in initiators of exenatide twice daily compared with other antidiabetic medication: a follow-up study. Diabet Med. 2012;29(11):1412–1418.
33. Flint A, Raben A, Astrup A, Holst JJ. Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans. J Clin Invest. 1998;101(3):515–520.
34. Secher A, Jelsing J, Baquero AF, et al. The arcuate nucleus mediates GLP-1 receptor agonist liraglutide-dependent weight loss. J Clin Invest. 2014;124(10):4473–4488.
35. Kothare PA, Linnebjerg H, Isaka Y, et al. Pharmacokinetics, pharmacodynamics, tolerability, and safety of exenatide in Japanese patients with type 2 diabetes mellitus. J Clin Pharmacol. 2008;48(12):1389–1399.
36. Gustavson SM, Chen D, Somayaji V, et al. Effects of a long-acting GLP-1 mimetic (PF-04603629) on pulse rate and diastolic blood pressure in patients with type 2 diabetes mellitus. Diabetes Obes Metab. 2011;13(11):1056–1058.
37. Blair HA, Keating GM. Albiglutide: a review of its use in patients with type 2 diabetes mellitus. Drugs. 2015;75(6):651–663.
38. Jendle J, Grunberger G, Blevins T, Giorgino F, Hietpas RT, Botros FT. Efficacy and safety of dulaglutide in the treatment of type 2 diabetes: a comprehensive review of the dulaglutide clinical data focusing on the AWARD phase 3 clinical trial program. Diabetes Metab Res Rev. 2016;32(8):776–790.
39. Kim YG, Hahn S, Oh TJ, Park KS, Cho YM. Differences in the HbA1c-lowering efficacy of glucagon-like peptide-1 analogues between Asians and non-Asians: a systematic review and meta-analysis. Diabetes Obes Metab. 2014;16(10):900–909.
40. Blundell J, Finlayson G, Buhl Axelsen M, et al. Effects of once-weekly semaglutide on appetite, energy intake, control of eating, food preference and body weight in subjects with obesity. Diabetes Obes Metab. 2017;19(9):1242–1251.
41. Seino Y, Kuwata H, Yabe D. Incretin-based drugs for type 2 diabetes: focus on East Asian perspectives. J Diabetes Investig. 2016;7(suppl 1):102–109.
42. Yabe D, Seino Y. Type 2 diabetes via β-cell dysfunction in East Asian people. Lancet Diabetes Endocrinol. 2016;4(1):2–3.
43. Riddle MC, Rosenstock J, Gerich J, Insulin Glargine 4002 Study Investigators. The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients. Diabetes Care. 2003;26(11):3080–3086.
44. Kahn SE, Haffner SM, Heise MA, et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med. 2006;355(23):2427–2443.
45. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet. 1998;352(9131):837–853.